Trial Profile

Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EGFRvIII directed CAR T cell tharapy Novartis/University of Pennsylvania (Primary)
Indications Glioblastoma
Focus Adverse reactions; First in man

Most Recent Events

04 Feb 2019 Status changed from active, no longer recruiting to discontinued.
14 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
24 May 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com